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Abstract
Background: Recent studies have demonstrated that the NKX3.1 protein is commonly down-
regulated in testicular germ cell tumors (TGCTs) and prostate carcinomas. The homeobox gene
NKX3.1 maps to chromosome band 8p21, which is a region frequently lost in prostate cancer, but
not in TGCT. Mutations have not been reported in the NKX3.1  sequence, and the gene is
hypothesized to be epigenetically inactivated. In the present study we examined the methylation
status of the NKX3.1 promoter in relevant primary tumors and cell lines: primary TGCTs (n = 55),
intratubular germ cell neoplasias (n = 7), germ cell tumor cell lines (n = 3), primary prostate
adenocarcinomas (n = 20), and prostate cancer cell lines (n = 3) by methylation-specific PCR and
bisulphite sequencing.
Results and Conclusions: Down-regulation of NKX3.1 expression was generally not caused by
promoter hypermethylation, which was only found in one TGCT. However, other epigenetic
mechanisms, such as modulation of chromatin structure or modifications of histones, may explain
the lack of NKX3.1 expression, which is seen in most TGCTs and prostate cancer specimens.
Background
The protein expression of the homeobox gene NK3 tran-
scription factor related locus 1 (NKX3.1) is highly specific for
the prostate and the testis [1-3], and is frequently lost in
cancers of these two tissue types [1,4,5]. NKX3.1 is located
in chromosome band 8p21 [2,6,7], a region that under-
goes frequent allelic imbalance in prostatic intraepithelial
neoplasia (PIN) and prostate carcinomas [8,9]. In mice,
targeted disruption of Nkx3.1 leads to prostatic epithelial
hyperplasia and dysplasia [10,11], and over-expression of
exogenous NKX3.1 suppresses growth and tumorigenicity
in human prostate carcinoma cell lines [12]. However, the
expression levels and possible role for NKX3.1 during
prostate cancer progression in humans is still being
debated [13-15]. No gene mutations of NKX3.1 have been
found [6], and NXK3.1  is therefore believed to be
Published: 03 February 2005
Molecular Cancer 2005, 4:8 doi:10.1186/1476-4598-4-8
Received: 19 November 2004
Accepted: 03 February 2005
This article is available from: http://www.molecular-cancer.com/content/4/1/8
© 2005 Lind et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Molecular Cancer 2005, 4:8 http://www.molecular-cancer.com/content/4/1/8
Page 2 of 5
(page number not for citation purposes)
epigenetically inactivated in the cases with loss of protein
expression [1,5,16]. Only one study has reported NKX3.1
protein expression in testicular germ cell tumors (TGCTs),
however the series analyzed was large, including a total of
more than 500 samples, and NKX3.1 was found absent in
all embryonal carcinomas and present in only 15–20% of
the seminomas as well as among the differentiated histo-
logical subtypes of germ cell tumors [5].
During the last decade, epigenetic changes in cancer have
been frequently reported and are now recognized to be at
least as common as genetic changes [17]. The best charac-
terized epigenetic mechanism is DNA hypermethylation,
in which cytosines located within selected CpG sites in the
gene promoters become methylated, thereby inactivating
gene expression. Several tumor suppressor genes are inac-
tivated by such promoter hypermethylation in various
cancer types [18,19]. In the present study we have per-
formed methylation-specific PCR (MSP) and bisulphite
sequencing of the NKX3.1 promoter in TGCTs and pros-
tate adenocarcinomas to examine whether this mecha-
nism may explain the commonly observed loss of NKX3.1
protein.
Results
Only one out of 54 TGCTs and none of the prostate aden-
ocarcinomas (n = 20), intratubular germ cell neoplasias
(n = 7), normal testis tissues (n = 4), or the cell lines (n =
6) displayed methylation when analyzed with MSP (Fig-
ure 1a). Bisulphite genomic sequencing of the tumors and
cell lines showed that all cytosines at non-CpG sites were
converted to thymine (Figure 1b). Only one sample dem-
onstrated overall methylation in the NKX3.1 sequence,
and this was the same sample that was positive for meth-
ylation from the MSP analysis. Interestingly, all the sam-
ples that were sequenced, including the normal blood,
unmethylated cell lines, and primary tumors, displayed
some extent of methylation (the majority below 25%) at
the cytosine in CpG number 21 (base 1914762, +1 bp
from transcription start). We detected a possible polymor-
phism in base 1914730 (+33 bp from transcription start
and 15 bp upstream of the coding sequence). In previous
sequences this site has been described as a guanine (Gene
bank accession number NT_023666, and AF24770). In
the cell lines, 5/6 contained adenosine in this position,
but all except the germ cell tumor cell lines NCCIT and
TERA2 were heterozygotes. In contrast, all 5 primary
tumors sequenced were homozygous for the adenosine
Representative results of the methylation analyses of the NKX3.1 promoter Figure 1
Representative results of the methylation analyses of the NKX3.1 promoter. (A) Methylation-specific PCR. A visible 
PCR product in Lanes U indicates the presence of unmethylated alleles whereas a PCR product in Lanes M indicates the pres-
ence of methylated alleles. The left panel illustrates the methylation status of selected TGCTs and the testicular cancer cell 
lines. Note the methylation of sample # 2110. The right panel shows the unmethylated status of primary prostate cancers and 
prostate cancer cell lines. Abbreviations: NB, normal blood (positive control for unmethylated samples); IVD, in vitro methylated 
DNA (positive control for methylated samples); neg, negative control (containing water as template); U, lane for unmethylated 
MSP product; M, lane for methylated MSP product. (B) Bisulphite sequencing. The bisulphite sequence allows a positive display 
of 5-methyl cytosines in the gene promoter as unmethylated cytosines appear as thymines, while 5-methylcytosines appear as 
cytosines in the final sequence. The left chromatogram represents a part of the unmethylated NKX3.1 promoter in the germ 
cell tumor cell line TERA2, including 11 CpG sites marked by underlined letters. The right chromatogram represents the 
unmethylated prostate cancer cell line DU145. Both sequences have been generated by reversing the respective anti-sense 
sequences by use of the software "Chromas".
U      M U      M U      M U      M U      M
1748 1838 2110 3493 TERA2 NCCIT IVD
U      M U      M U      M U      M
TERA1 NB
U      M U      M U      M U      M U      M U      M U      M U       M U      M
p156 p172 p175 LNCaP DU145 PC3 neg NB IVD neg p145
A)
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allele.
Discussion
We have previously reported that the protein expression
of NKX3.1 is virtually ubiquitously lost in TGCTs [5]. This
was done using a tissue microarray containing 510 testic-
ular tissue samples. NKX3.1 expression is known for 25 of
the TGCTs now analyzed for promoter hypermethylation
and 22 showed complete absence of protein. The down
regulation of NKX3.1 in TGCT has also been detected at
the mRNA level, both by quantitative RT-PCR [5] and
from an oligonucleotide microarray study including 20 of
the present TGCTs (Skotheim et al., submitted). This
simultaneous down regulation of both protein and
mRNA levels of NKX3.1 is consistent with epigenetic reg-
ulation, which is further supported by the fact that muta-
tions have not been detected in the NKX3.1 gene [6]. DNA
promoter hypermethylation is the best-characterized epi-
genetic change in cancer, and can be associated with gene
silencing. It was therefore of interest to analyze the meth-
ylation status of the NKX3.1 promoter in TGCT and pros-
tate cancer samples. However, with the exception of a
single TGCT, the NKX3.1 promoter was unmethylated in
the samples analyzed. The methylated TGCT was classi-
fied as a yolk sac tumor, and has also been demonstrated
to have promoter hypermethylation of several other genes
that are generally unmethylated in TGCTs (Lind et al.,
unpublished). We therefore consider this sample not to
be representative for the general TGCT epigenotype, nor
for the general epigenetic profile of yolk sac tumors. Thus,
we do not regard promoter hypermethylation as the gen-
eral mechanism of NKX3.1 down-regulation neither in
TGCT nor in prostate carcinomas.
We also studied cell lines since it can be argued that pres-
ence of normal cells as well as tumor heterogeneity may
mask cancer specific methylation in primary tumors.
LNCaP cells have previously been demonstrated to
express NKX3.1, in contrast to PC-3 and DU-145, which
do not express NKX3.1 since they lack a functional andro-
gen receptor [2]. The lack of NKX3.1 expression in PC-3
and DU-145 cells is not due to methylation. This was also
the case with the germ cell tumor cell lines. From Western
analysis, the cell line NCCIT had strong expression of
NKX3.1 whereas both TERA1 and TERA2 had no expres-
sion (data not shown).
The polymorphism in NKX3.1 that we detected 15 bases
upstream of the coding sequence has to our knowledge
not been described previously. It was identified by bisul-
phite sequencing of the cell lines and a subgroup of pri-
mary tumors, thus caution should be taken when
concluding from these results, since regular sequencing
analysis is the recommended approach for describing
sequence changes. As the polymorphism is located in the
promoter region of NKX3.1, it has no influence on the
protein structure. However, it can still have a potential
role in the transcriptional regulation of NKX3.1. A poly-
morphism in the coding sequence is also reported for
NKX3.1 [6].
All samples analyzed with bisulphite sequencing, includ-
ing cell lines expressing NKX3.1, as well as non-expressing
cell lines, demonstrated some degree of methylation in
the cytosine in CpG number 21. As this site-specific meth-
ylation included only one CpG site, it is unlikely that it
will have any regulating effect on gene expression. How-
ever, considering its intriguing location immediate
upstream of the transcription start point, this possibility
should not be excluded. There is also the possibility that
the apparent methylation could be due to a less efficient
bisulphite conversion for this site. In general, the bisul-
phite sequencing results showed that all cytosines at non-
CpG sites were converted to thymine (Figure 1b), but
sequence-specific partial resistance to this conversion may
lead to methylation artifacts, but only in rare cases, as has
been reported previously [20].
Conclusions
In summary, these data show that the previously reported
down-regulation of NKX3.1 in TGCTs and prostate carci-
nomas is not caused by promoter hypermethylation. Even
though the NKX3.1 promoter is unmethylated, the simul-
taneous down-regulation of mRNA and protein levels in
TGCTs and the absence of mutations still make other epi-
genetic mechanisms, such as modulation of chromatin
structure or modifications of histones, possible explana-
tions for loss of NKX3.1 expression in testicular- and pros-
tate cancers.
Materials and Methods
Primary tumors and cell lines
Included in the present study are primary TGCTs (n = 55),
intratubular germ cell neoplasias (also called carcinoma
in situ; n = 7), normal testis tissue (n = 4), germ cell tumor
cell lines (TERA1, TERA2, and NCCIT), prostate adenocar-
cinomas (n = 20), and prostate cancer cell lines (LNCaP,
PC-3, and DU-145). The primary TGCTs include all histo-
logical subtypes: seminomas, embryonal carcinomas, ter-
atomas, yolk sac tumors, and one choriocarcinoma,
classified according to the WHO's recommendations [21]
by a germ cell tumor reference pathologist using light
microscopic examination of hematoxylin and eosin
stained tissue sections. From our previous comparative
genome hybridization analysis, about half of the TGCTs
had a low-level copy number gain at chromosome 8, but
only rarely 8p deletions [22]. Primary prostate adenocar-
cinomas obtained from radical prostatectomy specimens
were graded according to the Gleason grading system [23]
using routinely stained tissue sections. The medianMolecular Cancer 2005, 4:8 http://www.molecular-cancer.com/content/4/1/8
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Gleason score of prostate adenocarcinomas was 7 (range:
4 – 8). The prostate carcinomas were all of pTNM stage 2
and 3, and included 10 samples with 8p deletions (among
other cytogenetic aberrations), 3 samples with copy
number changes not involving the 8p region, and 7 sam-
ples with no copy number changes (Ribeiro et al.,
submitted).
Methylation-specific PCR
The DNA samples were initially bisulphite modified
[24,25], which converts unmethylated but not methylated
cytosines to uracil. All samples were subsequently submit-
ted to MSP analysis [26] using PCR primers specific to






Probe AS, Oslo, Norway). The two fragments were ampli-
fied by the Fast Star DNA polymerase (Roche Ltd, Basel,
Switzerland) in a reaction containing 1.5 mM Mg2+. We
used a 58°C annealing temperature for both primer sets.
Bisulphite treated DNA from normal blood (NB) and Sss1
methyltransferase (New England Biolabs Inc., Beverly,
MA, USA) in vitro treated placenta DNA (IVD; Sigma
Chemical Co., St. Louis, MO, USA) represented the
unmethylated positive control and the methylated posi-
tive control, respectively. Water, replacing bisulphite
treated template, was the negative control in both
reactions.
Bisulphite sequencing
Bisulphite sequencing allows a positive display of 5-
methyl cytosines in the gene promoter after bisulphite
modification as unmethylated cytosines appear as thym-
ines, while 5-methylcytosines appear as cytosines in the
final sequence [27]. A subset of the samples (n = 11) were
bisulphite sequenced, including all 6 cell lines, 3 TGCTs,
and 2 prostate adenocarcinomas. Additionally, NB and
IVD were bisulphite sequenced as positive controls for
unmethylated and methylated sequence, respectively. The
NKX3.1 bisulphite sequence fragment (Gene bank acces-
sion number NT_023666 (minus strand), bases 1914526
to 1914961) was 436 bp long and covered 52 CpG sites in
the promoter and first exon of the gene. We designed
bisulphite sequencing primers (MedProbe) with the fol-
lowing sequences; sense:
5'ATTGGGGAAGGAGAGGGAATTG3', antisense:
5'CCTCTAACTCTAACTCTAACTCC3'. The Mg2+  content
of the reaction was 1.3 mM, the enzyme used was HotStar-
Taq™ DNA polymerase (QIAGEN Inc., Valencia, CA,
USA), and the annealing temperature 52°C. The PCR frag-
ments were eluted from a 2% agarose gel (BioRad Labora-
tories Inc, CA, USA) containing ethidium bromide, by the
MinElute™Gel Extraction kit (QIAGEN), and sequenced
with the dGTP BigDye Terminator Cycle Sequencing
Ready Reaction kit (Applied Biosystems, Foster City, CA)
in an ABI Prism 377 Sequencer (Applied Biosystems). The
bisulphite sequencing results were scored according to
Melki et al. where the amount of methylcytosine of each
CpG dinucleotide is quantified by comparing the peak
height of the cytosine signal with the sum of the cytosine
and thymine peak height signals [28].
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